ArticleCancer medicine2025
CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundActivating colony-stimulating factor 3 receptor (CSF3R) mutations are uncommon in acute myeloid leukemia (AML), and their prognostic significance remains unclear.
methodsWe compared clinical, treatment response, and survival data between CSF3R-mutated and CSF3R-wild-type AML patients.
resultsCSF3R-mutated cases presented a distinct molecular profile, with T618I and T640A being the most frequent variants. Common molecular aberrations included CEBPA bZip mutations (40%) and CBF fusions (23%), as well as secondary-type AML-associated mutations such as those in ASXL1, SRSF2, and EZH2. In contrast, NPM1 mutations were significantly less common in CSF3R-mutated patients (p = 0.03). Induction responses were poorer in CSF3R-mutated AML patients, with lower complete remission (55.6% vs. 78.8%, p = 0.004), reduced measurable residual disease (MRD) negativity (53.3% vs. 87.6%, p < 0.001), and shorter MRD maintenance duration (5.4 vs. 21.6 months, p < 0.001). According to the logistic regression analysis, CSF3R mutation emerged as an independent predictor of induction failure (p < 0.001). Survival outcomes were also inferior: the median overall survival (OS) was 20.7 months versus not reached (p = 0.0013), and progression-free survival was 9.4 versus 63.6 months (p < 0.0001). The adverse impact of CSF3R mutations was most pronounced in CEBPA bZip AML. CSF3R mutations abrogated the expected favorable prognosis (3-year OS: 44.2% vs. 88.2%, p = 0.0008). Conversely, CSF3R status did not affect outcomes in CBF-rearranged patients (p = 0.70).
conclusionsCSF3R mutations define a distinct, high-risk AML subset characterized by an inferior treatment response and survival, warranting incorporation into future risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.